Wegovy (Semaglutide 2.4 mg) in Women 65 and Older: What You Need to Know

Is Wegovy Approved for Women Over 65, and Do Older Women Actually Use It?

Wegovy carries FDA approval for chronic weight management in adults, with no stated upper age boundary in the label. So prescribing it to a 68-year-old woman is not technically off-label in the way that, say, prescribing it to a 14-year-old would be. What makes older women a distinct clinical category is the evidence gap: the STEP 1 trial, the foundational Phase 3 study that led to Wegovy's 2021 approval, enrolled participants with a mean age of 46. Women 65 and older made up a small fraction of the study population, and the published subgroup data for that age band is sparse enough that extrapolating the main efficacy findings to your situation requires real caution.

Obesity affects roughly 42% of U.S. Adults aged 60 to 79, and the proportion of older women seeking GLP-1 therapy is rising quickly. That clinical reality is colliding with a thin evidence base. What follows is what the data actually shows, and where it runs out.

What the FDA Label Says About Age

The prescribing information for Wegovy notes that clinical studies did not include sufficient numbers of patients 65 and older to determine whether they respond differently from younger patients. The label does not recommend dose adjustment based on age alone, but it flags that older adults are more likely to have conditions, such as reduced renal function or polypharmacy, that demand closer monitoring.

How Prevalent Is Wegovy Use in Older Women?

Real-world prescription data from U.S. Pharmacy claims show semaglutide prescriptions in adults 65 and older growing at roughly the same rate as younger cohorts since 2022, though absolute numbers remain lower. Women fill GLP-1 prescriptions at higher rates than men across all age groups, a pattern consistent with women making up the majority of weight-loss-seeking patients in clinical practice.

How Wegovy Works, and Why Female Physiology at 65+ Changes the Picture

Semaglutide is a GLP-1 receptor agonist. It binds GLP-1 receptors in the hypothalamus to reduce appetite, slows gastric emptying, and increases insulin secretion in a glucose-dependent fashion. At the 2.4 mg weekly maintenance dose, it produces appetite suppression significant enough to drive the 14.9% average body-weight reduction seen in STEP 1 over 68 weeks.

Postmenopause Physiology Shifts the Risk Profile

After menopause, estrogen withdrawal reshapes body composition in ways that interact directly with the weight-loss mechanism of GLP-1 drugs.

Estrogen normally supports lean mass preservation and bone mineral density. Its loss drives a shift toward central adiposity, reduced skeletal muscle mass, and accelerated bone resorption. A woman who loses 15% of her body weight on Wegovy at age 68 may lose a disproportionate share of that weight as muscle rather than fat, a phenomenon called sarcopenic obesity. Research published in JAMA Internal Medicine found that in GLP-1 trials broadly, roughly 25 to 39% of total weight lost was lean mass, not fat. That fraction is likely higher in older, postmenopausal women based on known age-related muscle physiology, though head-to-head data in women 65-plus on semaglutide specifically does not yet exist.

GLP-1 Receptors and Bone

GLP-1 receptors are expressed in osteoblasts, the cells that build bone. Some preclinical and observational data suggest GLP-1 agonists may have a protective effect on bone turnover markers. The STEP 1 trial did not report fracture outcomes as a primary endpoint. A 2023 review in the Journal of Clinical Endocrinology and Metabolism found no signal of increased fracture risk with GLP-1 agonists in the populations studied, but those populations skewed younger and heavier than a typical 67-year-old postmenopausal woman presenting with moderate obesity.

For older women already at fracture risk, the question is not settled. If you have osteopenia or osteoporosis, that needs to be part of the conversation before starting.

Pharmacokinetics in Older Women

Semaglutide is a large peptide with subcutaneous bioavailability near 89% and a half-life of approximately 7 days, which is why once-weekly dosing works. Renal clearance of the drug itself is not the primary elimination route, so kidney function does not directly alter semaglutide exposure. But older women are more prone to nausea-driven dehydration, which can concentrate nephrotoxic drugs they may be taking concurrently. Gastrointestinal side effects require more proactive management in this group.

Efficacy in Women 65 and Older: What the Evidence Actually Shows

The honest answer is that strong, age-stratified, sex-stratified data on Wegovy in women over 65 is limited.

STEP Trial Subgroup Data

The STEP program included five major trials. STEP 1, STEP 2 (type 2 diabetes), STEP 3 (intensive behavioral therapy), and STEP 4 (withdrawal) all had mean participant ages in the mid-40s to early 50s. None published primary analyses stratified by both age 65-plus and sex. The SELECT cardiovascular outcomes trial, which used the same 2.4 mg semaglutide dose in adults with established cardiovascular disease and overweight or obesity, had a mean participant age of 61.6 years, but women made up only 27.5% of that cohort. Weight loss in SELECT averaged approximately 9.4% at 3 years, somewhat lower than in STEP 1, which may reflect the older, higher-comorbidity population.

What Older Women Can Reasonably Expect

Weight loss is likely to occur, though possibly at a modestly lower magnitude than in younger cohorts, based on the SELECT signal and known age-related metabolic changes. Cardiovascular risk reduction, a major benefit in SELECT where semaglutide cut major adverse cardiovascular events by 20% versus placebo, may be a compelling reason to consider therapy in an older woman with cardiac risk factors, independent of the weight number alone.

Functional Outcomes Matter More at This Life Stage

For a 70-year-old woman, the clinical question is not just the number on the scale. It is whether weight loss translates to better mobility, reduced knee pain, improved glucose control, and lower cardiovascular risk, without triggering falls from muscle weakness or fractures from bone loss. That framing is not how the STEP trials were designed, and it is an honest evidence gap.

A practical clinical framework for women 65 and older considering Wegovy:

1. Baseline assessment first. Dual-energy X-ray absorptiometry (DEXA) for bone density and body composition, grip strength or gait speed testing, and renal function panel before starting.
2. Protein intake target. Aim for at least 1.2 g of protein per kilogram of body weight daily during active weight loss to counter lean mass loss, based on ESPEN geriatric nutrition guidelines.
3. Resistance training is non-negotiable. Structured resistance exercise at least twice weekly to preserve muscle mass. GLP-1 therapy without an exercise plan in a 65-plus woman is a formula for sarcopenia.
4. Monitoring interval. Recheck body composition at 6 months, not just weight.
5. Reassess at one year. If lean mass has dropped more than 5% from baseline, a team discussion about dose reduction or discontinuation is warranted.

Conditions Common in Older Women That Wegovy May Help or Complicate

Postmenopausal Metabolic Syndrome

Central adiposity, insulin resistance, elevated triglycerides, and hypertension cluster together after menopause. Semaglutide addresses most of these directly. In the STEP 1 trial, participants on semaglutide saw significant improvements in waist circumference, fasting glucose, blood pressure, and lipids compared to placebo. For a postmenopausal woman with this cluster, the cardiovascular case for GLP-1 therapy can be strong.

Type 2 Diabetes in Postmenopausal Women

If you have type 2 diabetes, Wegovy at 2.4 mg is distinct from Ozempic at 0.5 to 2.0 mg, though both use semaglutide. The STEP 2 trial studied semaglutide 2.4 mg specifically in adults with type 2 diabetes and obesity, showing a mean 9.6% weight reduction at 68 weeks versus 3.4% with placebo. Hypoglycemia risk in older women on concomitant sulfonylureas or insulin warrants careful medication reconciliation.

Osteoarthritis and Mobility

Excess weight is the single largest modifiable risk factor for knee osteoarthritis. Weight loss of 10% or more is associated with clinically meaningful pain reduction. For an older woman whose primary complaint is knee pain limiting activity, this benefit is real and documented. The concern is that if muscle loss accompanies weight loss, joint stability may worsen even as load decreases.

Hypothyroidism

Older women have a higher prevalence of hypothyroidism than any other demographic. Thyroid function does not directly alter semaglutide pharmacokinetics, but undertreated hypothyroidism blunts weight loss response to any therapy. TSH should be optimized before attributing treatment failure to the drug.

Female Pattern Hair Loss

Rapid weight loss of any kind, including on GLP-1 therapy, can trigger telogen effluvium, a temporary but distressing diffuse hair shed. Older women may already have androgenetic hair thinning. While the hair loss is typically self-limiting at 3 to 6 months, it is worth discussing upfront.

Dosing in Women 65 and Older

The approved titration schedule for Wegovy is the same regardless of age:

| Week | Dose | |------|------| | 1 to 4 | 0.25 mg subcutaneous weekly | | 5 to 8 | 0.5 mg subcutaneous weekly | | 9 to 12 | 1.0 mg subcutaneous weekly | | 13 to 16 | 1.7 mg subcutaneous weekly | | 17 onward | 2.4 mg subcutaneous weekly (maintenance) |

The label does not require age-based dose adjustment. For older women with significant nausea or poor tolerance at any step, extending the time at a given dose before advancing is a reasonable clinical strategy, though this is not explicitly studied in women 65-plus. Some clinicians maintain older patients at 1.7 mg if the 2.4 mg dose causes persistent nausea or functional decline, accepting slightly less weight loss in exchange for better tolerance. This approach is not FDA-endorsed but reflects pragmatic geriatric prescribing principles.

Pregnancy, Lactation, and Contraception

Most women at 65 and older are well past their reproductive years. Natural menopause, defined as 12 consecutive months without a menstrual period, occurs at a median age of 51.3 years in the United States, so pregnancy is not a clinical concern for the vast majority of women in this age group.

For completeness and for any woman near the age of 65 who has not confirmed menopause, the following applies.

Pregnancy: Wegovy is contraindicated in pregnancy. Animal studies showed fetal harm at clinically relevant exposures. The FDA label for semaglutide states that the drug should be discontinued at least 2 months before a planned pregnancy because of its long half-life. Human data on fetal outcomes is limited, and the drug is classified as causing fetal risk based on animal data.

Contraception: Any woman who has not had 12 consecutive months without a period, even with irregular cycles, should use reliable contraception while on Wegovy. Semaglutide slows gastric emptying, which may reduce oral contraceptive absorption, particularly during the titration phase. Non-oral methods (IUD, implant, patch, ring) avoid this interaction.

Lactation: It is not known whether semaglutide transfers into human breast milk at physiologically relevant levels. Given the age group addressed in this article, breastfeeding is not clinically applicable for virtually all readers.

Who This Is Right For, and Who Should Pause

Strong Candidates Among Women 65 and Older

• Postmenopausal women with BMI ≥30, or BMI ≥27 with established cardiovascular disease, type 2 diabetes, or obstructive sleep apnea
• Women with a cardiovascular event history who did not respond to lifestyle intervention alone
• Older women with severe knee osteoarthritis where weight loss would meaningfully reduce surgical risk
• Women whose primary care physician and cardiologist are aligned on the risk-benefit calculation

Women Who Should Proceed With Caution or Not at All

• Women with a personal or first-degree family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia type 2. Wegovy carries a boxed warning for this risk, observed in animal studies.
• Women with a history of pancreatitis
• Women with significant sarcopenia at baseline, where further muscle loss could impair functional independence
• Women with a history of gastroparesis or severe gastrointestinal dysmotility
• Women with severe renal impairment on nephrotoxic medications whose hydration status is already marginal
• Women with a BMI below 27 who are seeking the drug for reasons other than weight-related comorbidity management

Side Effects That Hit Differently at 65 and Older

The most common side effects of Wegovy are gastrointestinal: nausea, vomiting, diarrhea, and constipation. In the STEP 1 trial, nausea occurred in 44% of semaglutide participants versus 16% of placebo participants. For older women, these effects carry additional consequences.

Dehydration. Nausea-driven reduced fluid intake in a woman who may already have diminished thirst sensation can cause acute kidney injury, orthostatic hypotension, and electrolyte disturbances. Falls risk rises.

Drug interactions via reduced absorption. Levothyroxine, bisphosphonates, and oral medications that require consistent gastrointestinal transit for absorption can behave unpredictably during the titration period when gastric emptying is most affected.

Gallbladder disease. Rapid weight loss increases gallstone risk. The STEP 1 trial reported cholelithiasis in 1.6% of semaglutide participants versus 0.7% of placebo. Older women already carry higher baseline gallstone prevalence.

Fatigue and appetite suppression beyond what is therapeutic. Some older women become so appetite-suppressed that caloric intake drops below what is needed to maintain muscle. A registered dietitian experienced in geriatric nutrition should be part of the care team.

The Evidence Gap: What We Still Do Not Know

Women have been historically underrepresented in clinical trials. Older women are doubly underrepresented. No published RCT has examined Wegovy with primary endpoints in women 65 and older as a distinct population. The data we have comes from:

• Subgroup analyses with small numbers and insufficient statistical power
• The SELECT trial, where women were a minority and mean age was 61.6
• Mechanistic and observational data extrapolated from younger cohorts

"The absence of adequate evidence is not the same as evidence of absence of benefit, but it does mean that an older woman starting semaglutide is, in a meaningful sense, making a decision ahead of the data," says Maya Okafor, MD, WomanRx clinical reviewer and board-certified internist with a focus on women's metabolic health. "That is not automatically a reason to decline therapy, but it is a reason to monitor more closely than trials currently tell us to."

This honesty matters. If a clinician tells you that Wegovy is fully validated for women your age with strong trial data, that is not accurate. The benefit-risk case may still favor treatment in your specific situation. It just needs to be built on the actual evidence, not an extrapolation presented as certainty.

Monitoring Plan for Older Women on Wegovy

The standard follow-up intervals recommended in obesity medicine guidelines are not specifically designed for older women. Based on available geriatric prescribing literature and consensus obesity medicine guidance from AACE/ACE, the following monitoring schedule reflects what closer attention looks like for this age group:

Before starting:

• Body composition (DEXA preferred) or validated lean mass surrogate
• Fasting glucose and HbA1c
• Comprehensive metabolic panel including renal function
• TSH
• DEXA bone density if not done in the past 2 years
• Medication reconciliation for drugs affected by slowed gastric emptying
• Functional assessment (gait speed, grip strength)

At 4 and 8 weeks:

• Tolerance review: nausea severity, hydration, weight
• Blood pressure (orthostatic if any dizziness)

At 3 months:

• Weight, blood pressure, glucose if diabetic
• Evaluate for dehydration markers

At 6 months:

• Repeat body composition if available
• HbA1c if diabetic
• Reassess functional capacity

At 12 months:

• Full panel as at baseline
• Shared decision-making about continuing, dose-adjusting, or stopping based on lean mass trajectory and functional outcomes